secwatch.observer — SEC 8-K summary
======================================

Issuer:     STRATA Skin Sciences, Inc. (SSKN)
CIK:        0001051514
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001140361-25-010713
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Strata Q4 rev +10% to $9.6M; net loss $4.5M; adj. EBITDA improves to $2.2M in 2024
--------------------------------------------------------------------------------

- Q4 2024 revenue $9.6M, up 10% from $8.7M; net loss $4.5M (EPS -$1.18 vs -$1.09).
- Full-year 2024 revenue $33.6M (flat); net loss $10.1M (EPS -$2.65).
- Gross margin improved to 60.1% in Q4 (480 bps YoY); non-GAAP adj. EBITDA $2.2M vs $1.0M.
- Domestic XTRAC units reduced to 864; avg rev per device up 6% to $5,906.
- International Q4 sales $4.1M (+41% YoY); cash $8.6M at year end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1051514/000114036125010713/0001140361-25-010713-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1051514/000114036125010713/ef20046329_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-010713

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer